A recent study indicates that individuals who discontinue new slimming jabs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a leading medical journal demonstrates that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying such treatments need to be cognizant of the potential of quick rebound weight gain when the treatment ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a return to original weight within about one and a half years.
Weighing Approaches
The study, which examined 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that individuals who lose weight through lifestyle changes alone typically have a more gradual weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Experts propose the way of the drugs accounts for the accelerated rebound.
The injections imitate a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside recommended lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the therapy might need to be long-term.
This view is echoed by drug manufacturers, who say that the results "underscore the persistent character of obesity," akin to managing conditions like hypertension.
User Testimonies
Individuals who have stopped the jabs describe a powerful resurgence of appetite.
"It was like something flipping and I was suddenly extremely hungry," described a patient.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural changes during therapy.
Significant Use
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is greater among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while the jabs are potent tools for weight loss, they are not a standalone fix and long-term success likely depends on integrated behavioural support.
